T ANTIGEN IN BREAST AND PANCREAS CARCINOMA DETECTION

T 抗原在乳腺癌和胰腺癌检测中的应用

• 批准号: 3165088
• 负责人: GEORG F SPRINGER
• 金额: $ 11.99万
• 依托单位: EVANSTON HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1980
• 资助国家: 美国
• 起止时间: 1980-04-01 至 1987-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3165088
• 关键词: adenocarcinoma; biopsy; breast neoplasm /cancer diagnosis; breast neoplasms; cellular immunity; delayed hypersensitivity; early diagnosis; human subject; human therapy evaluation; human tissue; humoral immunity; immunity; immunochemistry; immunotoxicity; lung neoplasms; mammography; migration inhibition factor; neoplasm /cancer chemotherapy; neoplasm /cancer immunodiagnosis; neoplasm /cancer immunotherapy; pancreas neoplasms; plaque assay; radioimmunoassay; tumor antigens

We plan to extend studies with our so far (greater than 350 patients) sensitive and specific immunoassays in the detection (including early) of breast-, lung-, and pancreas adeno carcinoma (CA), and other CAs. We use the human T -- anti-T system to measure cell-mediated (CMI) as well as humoral immune responses towards CA-associated T antigen. T antigen does not occur in reactive form in non-CA tissue. However, it is readily prepared by a multistep procedure and slight chemical degradation from healthy, outdated human red blood cells. Delayed-type skin hypersensitivity to erythrocyte-derived T antigen as well as humoral anti-T response to T, measured by a novel quantitative immunofluorescent assay using insolubilized T antigen (SPIA-T), had greater greater than 80 percent sensitivity and greater than 90 percent specificity in detection of adeno- and small cell CA; toward squamous cell CA only SPIA-T, which is readily performed quantitatively and repeatedly, had such sensitivity. We want to distinguish early CA from nonmalignant and borderline lesions, and monitor the effect of therapy on CA. We intend to establish a rapid, economic assay for diagnosis of and possibly screening for CA. We will focus on early detection and on monitoring for recurrences. We are developing 2 in vitro tests to measure CMI to T, to circumvent the inconveniences of the delayed-type hypersensitivity skin test. We will extend successful attempts by others and by us to relate density of T receptors on CA cells with aggressiveness, and also that of Tn receptors. Satisfactory (early) diagnosis of CA requires precise localization of minute CA in addition to detection. We plan to establish firmly our preliminary work with human [131I]- anti-T IgG to localize T-active TA3 mouse mammary adenoCA metastases by external scanning in a step towards pinpointing early human CA and metastases. Implications of our work may be far-reaching, as we and others have indications that we measure a dynamic interaction of the cancer patient's immune system with the T-specific structures of the tumor.

我们计划到目前为止扩展研究（大于350名患者） 检测（包括早期）的敏感和特定的免疫测定 乳腺癌，肺和胰腺癌（CA）和其他CAS。 我们使用 人类t--T抗T系统，用于测量细胞介导的（CMI）以及 对CA相关T抗原的体液免疫反应。 t抗原可以 在非CA组织中不以反应性形式发生。 但是，很容易 通过多步骤程序制备，从 健康，过时的人类红细胞。 延迟型皮肤 对红细胞衍生的T抗原和体液抗T的超敏反应 对T的响应，通过新型的定量免疫荧光测定法测量 使用不违反的T抗原（SPIA-T），其具有大于80％ 敏感性和大于90％的特异性检测 和小细胞Ca；朝向鳞状细胞CA仅SPIA-T，很容易 进行定量和反复的表现具有如此灵敏度。 我们想 区分早期CA与非恶性和边界病变，并监测 治疗对CA的影响。 我们打算建立快速，经济的 测定诊断和可能筛查的测定法。 我们将重点关注 早期检测和监测复发。 我们正在开发2个 体外测试以测量CMI至T，以避免不便 延迟型高敏性皮肤测试。 我们将扩大成功 他人和我们与Ca细胞上T受体密度相关的尝试 具有侵略性以及TN受体的侵略性。 令人满意（早期） 诊断CA还需要精确定位分钟CA。 检测。 我们计划与人类建立牢固的初步工作 [131i] -anti-T IgG定位T-Active TA3小鼠乳腺腺癌 通过外部扫描迈向指出早期人的转移 CA和转移。 像我们和我们一样，我们工作的含义可能是深远的 其他人有迹象表明我们衡量癌症的动态相互作用 患者的免疫系统具有肿瘤的T特异性结构。

项目成果

Delayed-type cutaneous hypersensitivity to Thomsen-Friedenreich (T) antigen in patients with pancreatic cancer.

胰腺癌患者对 Thomsen-Friedenreich (T) 抗原的迟发性皮肤超敏反应。

• DOI: 10.1016/0022-4804(83)90004-5
• 发表时间: 1983
• 期刊: The Journal of surgical research
• 作者: Goodale,RL;Springer,GF;Shearen,JG;Desai,PR;Tegtmeyer,H
• 通讯作者: Tegtmeyer,H

T/Tn antigen vaccine is effective and safe in preventing recurrence of advanced human breast carcinoma.

• DOI: 10.1089/cbr.1994.9.7
• 发表时间: 1994
• 期刊: Cancer biotherapy
• 作者: Georg F. Springer;P. Desai;H. Tegtmeyer;Sheila C. Carlstedt;Edward F. Scanlon